Novartis AG

Open: 105.91 Close: 106.31 Change: 0.4

Don't invest before reading what an AI found about Novartis AG Stock.

The game is changing. There is a new strategy to evaluate Novartis AG fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: Novartis, Voyager, Therapeutics, license, collaboration, agreement, AG, …

Concept Map

Semantic Network

Stock Summary

Novartis AG researches, develops, manufactures, markets, markets healthcare products. The company operates through two segments: Innovative Medicines and Sandoz. Novarti has a license and collaboration agreement with Alnylam Pharmaceuticals.

Today's Summary

Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Voyager Therapeutics shares soar 32% on news of deal with Novartes.

Today's News

Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Voyager Therapeutics shares soar 32% on news of deal with Novartes that includes up to $1.2 billion in milestones. Novartis AG (NVS) hits fresh high: Is there still room to run? Novartis Ag stock last closed at $106.31 , up 0.7% from the previous day, and has increased 17.08% in one year. Voyager Therapeutics enters capsid license agreement and strategic collaboration with novartis. Novartis Ag pays a dividend of 3.26% compared to the Drug Manufacturers - General industrys average dividend yield of 3.14%. Dividend payments have consistently grown over the past decade but have not remained stable. Novartis has figured Pluvicto could eventually reach more than $3 billion in peak sales if its late-stage development pans out. Voyager Therapeutics (NASDAQ:VYGR) skyrockets on ~$1.3b licensing deal with novartis. Novartis has signed a collaboration and capsid license agreement with Voyager Therapeutics to develop gene therapies for Huntingtons disease and spinal muscular atrophy.

Stock Profile

"Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland."

Keywords

How much time have you spent trying to decide whether investing in Novartis AG? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: Novartis, Voyager, Therapeutics, license, collaboration, agreement, AG, and the most common words in the summary are: novartis, stock, voyager, news, job, market, therapy, . One of the sentences in the summary was: Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #novartis #stock #voyager #news #job #market #therapy.